Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 255

1.

Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T-cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).

Canaani J, Labopin M, Huang XJ, Ciceri F, Van Lint MT, Bruno B, Santarone S, Diez-Martin JL, Blaise D, Chiusolo P, Wu D, Mohty M, Nagler A.

Br J Haematol. 2018 Aug 16. doi: 10.1111/bjh.15540. [Epub ahead of print]

PMID:
30117144
2.

HAPLOIENTICAL TRANSPLANTS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA: THE ROLE OF COMORBIDITY INDEX AND PRE-TRANSPLANT POSITRON EMISSION TOMOGRAPHY.

Marani C, Raiola AM, Morbelli S, Dominietto A, Ferrarazzo G, Avenoso D, Giannoni L, Varaldo R, Gualandi F, Grazia CD, Lamparelli T, Bregante S, Van Lint MT, Ibatici A, Bovis F, Lemoli RM, Gobbi M, Bacigalupo A, Angelucci E.

Biol Blood Marrow Transplant. 2018 Jul 21. pii: S1083-8791(18)30414-2. doi: 10.1016/j.bbmt.2018.07.025. [Epub ahead of print]

PMID:
30041010
3.

Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita.

Fioredda F, Iacobelli S, Korthof ET, Knol C, van Biezen A, Bresters D, Veys P, Yoshimi A, Fagioli F, Mats B, Zecca M, Faraci M, Miano M, Arcuri L, Maschan M, O'Brien T, Diaz MA, Sevilla J, Smith O, Peffault de Latour R, de la Fuente J, Or R, Van Lint MT, Tolar J, Aljurf M, Fisher A, Skorobogatova EV, Diaz de Heredia C, Risitano A, Dalle JH, Sedláček P, Ghavamzadeh A, Dufour C.

Br J Haematol. 2018 Jul 9. doi: 10.1111/bjh.15495. [Epub ahead of print]

PMID:
29984823
4.

Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide.

Shimoni A, Labopin M, Lorentino F, Van Lint MT, Koc Y, Gülbas Z, Tischer J, Bruno B, Blaise D, Pioltelli P, Afanasyev B, Ciceri F, Mohty M, Nagler A.

Leukemia. 2018 Jun 15. doi: 10.1038/s41375-018-0170-5. [Epub ahead of print]

PMID:
29907809
5.

Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT.

McLornan DP, Szydlo R, Robin M, van Biezen A, Koster L, Blok HJP, Van Lint MT, Finke J, Vitek A, Carlson K, Griskevicius L, Holler E, Itälä-Remes M, Schaap M, Socié G, Bay JO, Beguin Y, Bruno B, Cornelissen JJ, Gedde-Dahl T, Ljungman P, Rubio MT, Yakoub-Agha I, Klyuchnikov E, Olavarria E, Chalandon Y, Kröger N.

Br J Haematol. 2018 May 29. doi: 10.1111/bjh.15407. [Epub ahead of print]

PMID:
29808926
6.

Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants.

Metafuni E, Chiusolo P, Sica S, Laurenti L, Bregante S, Van Lint MT, Dominietto A, Angelucci E, Bacigalupo A.

Bone Marrow Transplant. 2018 May 24. doi: 10.1038/s41409-018-0200-y. [Epub ahead of print]

PMID:
29795416
7.

Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Salvatore D, Labopin M, Ruggeri A, Battipaglia G, Ghavamzadeh A, Ciceri F, Blaise D, Arcese W, Sociè G, Bourhis JH, Van Lint MT, Bruno B, Huynh A, Santarone S, Deconinck E, Mohty M, Nagler A.

Haematologica. 2018 Aug;103(8):1317-1328. doi: 10.3324/haematol.2018.189258. Epub 2018 May 10.

8.

High vs low dose cyclosporine-a, after allogeneic marrow transplantation in leukemia: Long term follow up of a randomized study.

Bacigalupo A, Van Lint MT, Sica S, Laurenti L, Rosales MB, Dominietto A, di Grazia C, Angelucci E.

Am J Hematol. 2018 May 4. doi: 10.1002/ajh.25131. [Epub ahead of print] No abstract available.

PMID:
29726028
9.

Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved?

Giammarco S, Peffault de Latour R, Sica S, Dufour C, Socie G, Passweg J, Kröger N, Petersen E, Van Lint MT, Oneto R, Signori A, Bacigalupo A; European Group for Blood and Marrow Transplantation Severe Aplastic Anemia Working Party.

Blood. 2018 Apr 26;131(17):1989-1992. doi: 10.1182/blood-2017-09-807859. Epub 2018 Mar 16. No abstract available.

PMID:
29549172
10.

Haploidentical transplantation outcomes for secondary acute myeloid leukemia: Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) study.

Li Z, Labopin M, Ciceri F, Blaise D, Tischer J, Ehninger G, Van Lint MT, Koc Y, Santarone S, Forcade E, Castagna L, Polge E, Mailhol A, Ruggeri A, Mohty M, Savani BN, Nagler A.

Am J Hematol. 2018 Jun;93(6):769-777. doi: 10.1002/ajh.25087. Epub 2018 Apr 11.

PMID:
29536560
11.

First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001-2012.

Bacigalupo A, Oneto R, Schrezenmeier H, Hochsmann B, Dufour C, Kojima S, Zhu X, Chen X, Issaragrisil S, Chuncharunee S, Jeong DC, Giammarco S, Van Lint MT, Zheng Y, Vallejo C.

Am J Hematol. 2018 May;93(5):643-648. doi: 10.1002/ajh.25081. Epub 2018 Mar 23.

PMID:
29498107
12.

T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Canaani J, Labopin M, Huang XJ, Arcese W, Ciceri F, Blaise D, Irrera G, Corral LL, Bruno B, Santarone S, Van Lint MT, Vitek A, Esteve J, Mohty M, Nagler A.

Am J Hematol. 2018 Jun;93(6):736-744. doi: 10.1002/ajh.25082. Epub 2018 Mar 23.

PMID:
29498106
13.

A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study.

Chiusolo P, Bug G, Olivieri A, Brune M, Mordini N, Alessandrino PE, Dominietto A, Raiola AM, Di Grazia C, Gualandi F, Van Lint MT, Ferrara F, Finizio O, Angelucci E, Bacigalupo A.

Biol Blood Marrow Transplant. 2018 Jun;24(6):1243-1249. doi: 10.1016/j.bbmt.2018.01.031. Epub 2018 Feb 5.

PMID:
29421292
14.

Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT.

Cesaro S, Crocchiolo R, Tridello G, Knelange N, Van Lint MT, Koc Y, Ciceri F, Gülbas Z, Tischer J, Afanasyev B, Bruno B, Castagna L, Blaise D, Mohty M, Irrera G, Diez-Martin JL, Pierelli L, Pioltelli P, Arat M, Delia M, Fagioli F, Ehninger G, Aljurf M, Carella AM, Ozdogu H, Mikulska M, Ljungman P, Nagler A, Styczynski J.

Bone Marrow Transplant. 2018 Apr;53(4):422-430. doi: 10.1038/s41409-017-0016-1. Epub 2018 Jan 12.

PMID:
29330396
15.

Haploidentical transplant in patients with myelodysplastic syndrome.

Robin M, Porcher R, Ciceri F, van Lint MT, Santarone S, Ehninger G, Blaise D, Güllbas Z, Gonzáles Muñiz S, Michallet M, Velardi A, Koster L, Maertens J, Sierra J, Selleslag D, Radujkovic A, Díez-Martin JL, Kanz L, Arroyo CH, Niederwieser D, Huang H, McDonald A, de Witte T, Koc Y, Kröger N.

Blood Adv. 2017 Sep 27;1(22):1876-1883. doi: 10.1182/bloodadvances.2017007146. eCollection 2017 Oct 10.

16.

Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT.

van Gorkom G, van Gelder M, Eikema DJ, Blok HJ, van Lint MT, Koc Y, Ciceri F, Beelen D, Chevallier P, Selleslag D, Blaise D, Foá R, Corradini P, Castagna L, Moreno C, Solano C, Müller LP, Tischer J, Hilgendorf I, Hallek M, Bittenbring J, Theobald M, Schetelig J, Kröger N; CLL subcommittee; Chronic Malignancies Working Party of the EBMT.

Bone Marrow Transplant. 2018 Mar;53(3):255-263. doi: 10.1038/s41409-017-0023-2. Epub 2017 Dec 18.

PMID:
29255169
17.

Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation.

Canaani J, Savani BN, Labopin M, Huang XJ, Ciceri F, Arcese W, Koc Y, Tischer J, Blaise D, Gülbas Z, Van Lint MT, Bruno B, Mohty M, Nagler A.

Am J Hematol. 2018 Feb;93(2):246-253. doi: 10.1002/ajh.24963. Epub 2017 Dec 6.

PMID:
29114918
18.

Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High-Dose Cyclophosphamide.

Raiola AM, Risitano A, Sacchi N, Giannoni L, Signori A, Aquino S, Bregante S, Di Grazia C, Dominietto A, Geroldi S, Ghiso A, Gualandi F, Lamparelli T, Tedone E, Van Lint MT, Varaldo R, Ibatici A, Marani C, Marotta S, Guolo F, Avenoso D, Garbarino L, Pane F, Bacigalupo A, Angelucci E.

Biol Blood Marrow Transplant. 2018 Jan;24(1):119-126. doi: 10.1016/j.bbmt.2017.10.002. Epub 2017 Oct 9.

PMID:
29024804
19.

Steroid treatment of acute graft-versus-host disease grade I: a randomized trial.

Bacigalupo A, Milone G, Cupri A, Severino A, Fagioli F, Berger M, Santarone S, Chiusolo P, Sica S, Mammoliti S, Sorasio R, Massi D, Van Lint MT, Raiola AM, Gualandi F, Selleri C, Sormani MP, Signori A, Risitano A, Bonifazi F; Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

Haematologica. 2017 Dec;102(12):2125-2133. doi: 10.3324/haematol.2017.171157. Epub 2017 Sep 29.

20.

Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System.

Della Porta MG, Jackson CH, Alessandrino EP, Rossi M, Bacigalupo A, van Lint MT, Bernardi M, Allione B, Bosi A, Guidi S, Santini V, Malcovati L, Ubezio M, Milanesi C, Todisco E, Voso MT, Musto P, Onida F, Iori AP, Cerretti R, Grillo G, Molteni A, Pioltelli P, Borin L, Angelucci E, Oldani E, Sica S, Pascutto C, Ferretti V, Santoro A, Bonifazi F, Cazzola M, Rambaldi A.

Leukemia. 2017 Nov;31(11):2449-2457. doi: 10.1038/leu.2017.88. Epub 2017 Mar 21.

21.

Haploidentical bone marrow transplantation in patients with advanced myelodysplastic syndrome.

Varaldo R, Raiola AM, Di Grazia C, Aquino S, Beltrami G, Bregante S, Cruciani F, Dominietto A, Ghiso A, Giannoni L, Gualandi F, Ibatici A, Lamparelli T, Marani C, Van Lint MT, Santini V, Bacigalupo A, Angelucci E.

Am J Hematol. 2017 Jun;92(6):E117-E119. doi: 10.1002/ajh.24725. Epub 2017 Apr 29. No abstract available.

22.

Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation.

Della Porta MG, Gallì A, Bacigalupo A, Zibellini S, Bernardi M, Rizzo E, Allione B, van Lint MT, Pioltelli P, Marenco P, Bosi A, Voso MT, Sica S, Cuzzola M, Angelucci E, Rossi M, Ubezio M, Malovini A, Limongelli I, Ferretti VV, Spinelli O, Tresoldi C, Pozzi S, Luchetti S, Pezzetti L, Catricalà S, Milanesi C, Riva A, Bruno B, Ciceri F, Bonifazi F, Bellazzi R, Papaemmanuil E, Santoro A, Alessandrino EP, Rambaldi A, Cazzola M.

J Clin Oncol. 2016 Sep 6. pii: JCO673616. [Epub ahead of print]

23.

Failure to effectively treat chronic graft-versus-host disease: a strong call for prevention.

Bacigalupo A, Sica S, van Lint MT.

Haematologica. 2016 May;101(5):e214-5. doi: 10.3324/haematol.2015.138040. No abstract available.

24.

Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation.

Di Grazia C, Pozzi S, Geroldi S, Grasso R, Miglino M, Colombo N, Tedone E, Luchetti S, Lamparelli T, Gualandi F, Ibatici A, Bregante S, Van Lint MT, Raiola AM, Dominietto A, Varaldo R, Galaverna F, Ghiso A, Sica S, Bacigalupo A.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1242-1246. doi: 10.1016/j.bbmt.2016.03.005. Epub 2016 Mar 10.

25.

Improved Outcome of Alternative Donor Transplantations in Patients with Myelofibrosis: From Unrelated to Haploidentical Family Donors.

Bregante S, Dominietto A, Ghiso A, Raiola AM, Gualandi F, Varaldo R, Di Grazia C, Lamparelli T, Luchetti S, Geroldi S, Casarino L, Pozzi S, Tedone E, Van Lint MT, Galaverna F, Barosi G, Bacigalupo A.

Biol Blood Marrow Transplant. 2016 Feb;22(2):324-329. doi: 10.1016/j.bbmt.2015.09.028. Epub 2015 Oct 9.

26.

Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update.

Bacigalupo A, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, Bregante S, Van Lint MT, Geroldi S, Luchetti S, Grasso R, Pozzi S, Colombo N, Tedone E, Varaldo R, Raiola AM.

Bone Marrow Transplant. 2015 Jun;50 Suppl 2:S37-9. doi: 10.1038/bmt.2015.93.

PMID:
26039205
27.

DLI after haploidentical BMT with post-transplant CY.

Ghiso A, Raiola AM, Gualandi F, Dominietto A, Varaldo R, Van Lint MT, Bregante S, Di Grazia C, Lamparelli T, Galaverna F, Stasia A, Luchetti S, Geroldi S, Grasso R, Colombo N, Bacigalupo A.

Bone Marrow Transplant. 2015 Jan;50(1):56-61. doi: 10.1038/bmt.2014.217. Epub 2014 Oct 13.

PMID:
25310304
28.

Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.

Ustun C, Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S, Shanley R, Hogan WJ, Perales MA, Shore T, Baurmann H, Stuart R, Gruhn B, Doubek M, Hsu JW, Tholouli E, Gromke T, Godley LA, Pagano L, Gilman A, Wagner EM, Shwayder T, Bornhäuser M, Papadopoulos EB, Böhm A, Vercellotti G, Van Lint MT, Schmid C, Rabitsch W, Pullarkat V, Legrand F, Yakoub-Agha I, Saber W, Barrett J, Hermine O, Hagglund H, Sperr WR, Popat U, Alyea EP, Devine S, Deeg HJ, Weisdorf D, Akin C, Valent P.

J Clin Oncol. 2014 Oct 10;32(29):3264-74. doi: 10.1200/JCO.2014.55.2018. Epub 2014 Aug 25.

29.

[Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation].

Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, Burns LJ, Chaudhri N, Davies S, Okamoto S, Seber A, Socie G, Szer J, Van Lint MT, Wingard JR, Tichelli A; Center for International Blood and Marrow Transplant Research (CIBMTR); American Society for Blood and Marrow Transplantation (ASBMT); European Group for Blood and Marrow Transplantation (EBMT); Asia-Pacific Blood and Marrow Transplantation Group (APBMT); Bone Marrow Transplantation Society of Australia and New Zeland (BMTSANZ); East Mediterrnean Blood and Marrow Transplantation Group (EMBMT); Sociedale Brasileira de Transplante de Medula Ossea (SBTMO).

Rinsho Ketsueki. 2014 Jun;55(6):607-32. Japanese.

PMID:
24975331
30.

Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.

Raiola AM, Dominietto A, di Grazia C, Lamparelli T, Gualandi F, Ibatici A, Bregante S, Van Lint MT, Varaldo R, Ghiso A, Gobbi M, Carella AM, Signori A, Galaverna F, Bacigalupo A.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1573-9. doi: 10.1016/j.bbmt.2014.05.029. Epub 2014 Jun 5.

31.

CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation.

Stasia A, Ghiso A, Galaverna F, Raiola AM, Gualandi F, Luchetti S, Pozzi S, Varaldo R, Lamparelli T, Bregante S, Van Lint MT, di Grazia C, Bacigalupo A.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1440-3. doi: 10.1016/j.bbmt.2014.05.016. Epub 2014 May 24.

32.

Systemic lupus erythematosus complicated with thymoma and pure red cell aplasia (PCRA). CR of both complications following thymectomy and allogeneic haematopoietic SCT (HSCT), but persistence of antinuclear antibodies (ANA).

Marmont AM, Bacigalupo A, Gualandi F, Bregante S, van Lint MT, Geroldi S.

Bone Marrow Transplant. 2014 Jul;49(7):982-3. doi: 10.1038/bmt.2014.68. Epub 2014 May 12. No abstract available.

PMID:
24820215
33.

Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R.

Della Porta MG, Alessandrino EP, Bacigalupo A, van Lint MT, Malcovati L, Pascutto C, Falda M, Bernardi M, Onida F, Guidi S, Iori AP, Cerretti R, Marenco P, Pioltelli P, Angelucci E, Oneto R, Ripamonti F, Bernasconi P, Bosi A, Cazzola M, Rambaldi A; Gruppo Italiano Trapianto di Midollo Osseo.

Blood. 2014 Apr 10;123(15):2333-42. doi: 10.1182/blood-2013-12-542720. Epub 2014 Feb 20.

34.

Increase of suicide and accidental death after hematopoietic stem cell transplantation: a cohort study on behalf of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Tichelli A, Labopin M, Rovó A, Badoglio M, Arat M, van Lint MT, Lawitschka A, Schwarze CP, Passweg J, Socié G.

Cancer. 2013 Jun 1;119(11):2012-21. doi: 10.1002/cncr.27987. Epub 2013 Mar 19.

35.

Sjögren's syndrome associated chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) treated with autologous and subsequently allogeneic haematopoietic SCT (HSCT).

Bregante S, Gualandi F, van Lint MT, Schenone A, Bacigalupo A, Marmont AM.

Bone Marrow Transplant. 2013 Aug;48(8):1139-40. doi: 10.1038/bmt.2013.18. Epub 2013 Mar 18. No abstract available.

PMID:
23503533
36.

Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression.

Pozzi S, Geroldi S, Tedone E, Luchetti S, Grasso R, Colombo N, Di Grazia C, Lamparelli T, Gualandi F, Ibatici A, Bregante S, Van Lint MT, Raiola AM, Dominietto A, Varaldo R, Signori A, Bacigalupo A.

Br J Haematol. 2013 Feb;160(4):503-9. doi: 10.1111/bjh.12181. Epub 2013 Jan 7.

PMID:
23294252
37.

Paternity wishes in long-term survivors after allogeneic hematopoietic SCT. A study of the late effects working party of the EBMT.

Rovó A, Aljurf M, Chiodi S, Spinelli S, Salooja N, Sucak G, Hunter A, Kim TS, Socié G, van Lint MT, Passweg JR, Arat M, Badoglio M, Tichelli A.

Bone Marrow Transplant. 2013 Jun;48(6):878-9. doi: 10.1038/bmt.2012.255. Epub 2013 Jan 7. No abstract available.

PMID:
23292242
38.

Standard treatment of acquired SAA in adult patients 18-40 years old with an HLA-identical sibling donor.

Aljurf M, Al-Zahrani H, Van Lint MT, Passweg JR.

Bone Marrow Transplant. 2013 Feb;48(2):178-9. doi: 10.1038/bmt.2012.223. Epub 2012 Nov 19. Review.

PMID:
23165494
39.

Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.

Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, Bregante S, Van Lint MT, Geroldi S, Luchetti S, Ballerini F, Miglino M, Varaldo R, Bacigalupo A.

Biol Blood Marrow Transplant. 2013 Jan;19(1):117-22. doi: 10.1016/j.bbmt.2012.08.014. Epub 2012 Aug 29.

40.

Ongoing graft-versus-host disease is a risk factor for azoospermia after allogeneic hematopoietic stem cell transplantation: a survey of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation.

Rovó A, Aljurf M, Chiodi S, Spinelli S, Salooja N, Sucak G, Hunter A, Kim TS, Socié G, van Lint MT, Passweg JR, Arat M, Badoglio M, Tichelli A; Late Effects Working Party of the EBMT.

Haematologica. 2013 Mar;98(3):339-45. doi: 10.3324/haematol.2012.071944. Epub 2012 Aug 28.

41.

Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.

Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, Burns LJ, Chaudhri N, Davies S, Okamoto S, Seber A, Socie G, Szer J, Van Lint MT, Wingard JR, Tichelli A; Center for International Blood and Marrow Transplant Research (CIBMTR); American Society for Blood and Marrow Transplantation (ASBMT); European Group for Blood and Marrow Transplantation (EBMT); Asia-Pacific Blood and Marrow Transplantation Group (APBMT); Bone Marrow Transplant Society of Australia and New Zealand (BMTSANZ); East Mediterranean Blood and Marrow Transplantation Group (EMBMT); Sociedade Brasileira de Transplante de Medula Ossea (SBTMO).

Hematol Oncol Stem Cell Ther. 2012;5(1):1-30. doi: 10.5144/1658-3876.2012.1.

42.

Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.

Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, Burns LJ, Chaudhri N, Davies S, Okamoto S, Seber A, Socie G, Szer J, Van Lint MT, Wingard JR, Tichelli A; Center for International Blood and Marrow Transplant Research; American Society for Blood and Marrow Transplantation; European Group for Blood and Marrow Transplantation; Asia-Pacific Blood and Marrow Transplantation Group; Bone Marrow Transplant Society of Australia and New Zealand; East Mediterranean Blood and Marrow Transplantation Group; Sociedade Brasileira de Transplante de Medula Ossea.

Bone Marrow Transplant. 2012 Mar;47(3):337-41. doi: 10.1038/bmt.2012.5.

43.

Mortality after bloodstream infections in allogeneic haematopoietic stem cell transplant (HSCT) recipients.

Mikulska M, Del Bono V, Bruzzi P, Raiola AM, Gualandi F, Van Lint MT, Bacigalupo A, Viscoli C.

Infection. 2012 Jun;40(3):271-8. doi: 10.1007/s15010-011-0229-y. Epub 2011 Dec 21.

PMID:
22187340
44.

Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.

Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, Burns LJ, Chaudhri N, Davies S, Okamoto S, Seber A, Socie G, Szer J, Van Lint MT, Wingard JR, Tichelli A; Center for International Blood and Marrow Transplant Research (CIBMTR); American Society for Blood and Marrow Transplantation (ASBMT); European Group for Blood and Marrow Transplantation (EBMT); Asia-Pacific Blood and Marrow Transplantation Group (APBMT); Bone Marrow Transplant Society of Australia and New Zealand (BMTSANZ); East Mediterranean Blood and Marrow Transplantation Group (EMBMT),; Sociedade Brasileira de Transplante de Medula Ossea (SBTMO).

Biol Blood Marrow Transplant. 2012 Mar;18(3):348-71. doi: 10.1016/j.bbmt.2011.12.519. Epub 2011 Dec 13.

45.

In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT.

Dominietto A, Tedone E, Soracco M, Bruno B, Raiola AM, Van Lint MT, Geroldi S, Lamparelli T, Galano B, Gualandi F, Frassoni F, Bacigalupo A.

Bone Marrow Transplant. 2012 Jan;47(1):101-6. doi: 10.1038/bmt.2011.28. Epub 2011 Apr 4.

PMID:
21460867
46.

Helical tomotherapy targeting total bone marrow after total body irradiation for patients with relapsed acute leukemia undergoing an allogeneic stem cell transplant.

Corvò R, Zeverino M, Vagge S, Agostinelli S, Barra S, Taccini G, Van Lint MT, Frassoni F, Bacigalupo A.

Radiother Oncol. 2011 Mar;98(3):382-6. doi: 10.1016/j.radonc.2011.01.016. Epub 2011 Feb 19.

PMID:
21339008
47.

Persistence of a positive (1,3)-beta-D-glucan test after clearance of candidemia in hematopoietic stem cell transplant recipients.

Mikulska M, Furfaro E, Del Bono V, Gualandi F, Van Lint MT, Miletich F, Bacigalupo A, Viscoli C.

Clin Vaccine Immunol. 2011 Mar;18(3):518-9. doi: 10.1128/CVI.00513-10. Epub 2011 Jan 19.

48.

Late complications after hematopoietic stem cell transplantation.

Tichelli A, Rovó A, Passweg J, Schwarze CP, Van Lint MT, Arat M, Socié G; Late Effects Working Party of the European Group for Blood and Marrow Transplantation.

Expert Rev Hematol. 2009 Oct;2(5):583-601. doi: 10.1586/ehm.09.48. Review.

PMID:
21083023
49.

Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.

Coppoletta S, Tedone E, Galano B, Soracco M, Raiola AM, Lamparelli T, Gualandi F, Bregante S, Ibatici A, di Grazia C, Dominietto A, Varaldo R, Bruno B, Frassoni F, Van Lint MT, Bacigalupo A.

Biol Blood Marrow Transplant. 2011 Jun;17(6):901-7. doi: 10.1016/j.bbmt.2010.10.003. Epub 2010 Oct 13.

50.

Risk factors for enterococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients.

Mikulska M, Del Bono V, Prinapori R, Boni L, Raiola AM, Gualandi F, Van Lint MT, Dominietto A, Lamparelli T, Cappellano P, Bacigalupo A, Viscoli C.

Transpl Infect Dis. 2010 Dec;12(6):505-12. doi: 10.1111/j.1399-3062.2010.00544.x.

PMID:
20636482

Supplemental Content

Loading ...
Support Center